An Expanded Access Programs (EAP) in US for Systemic Mastocytosis (SM) and gastrointestinal stromal tumors (GIST) patients
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Bezuclastinib (Primary)
- Indications Gastrointestinal stromal tumours; Systemic mastocytosis
- Focus Expanded access; Therapeutic Use
- 17 Jan 2025 New trial record
- 13 Jan 2025 According to a Cogent Biosciences media release, during Q1 2025, company plans to initiate Expanded Access Programs (EAP) in the U.S. for SM and GIST patients to receive investigational bezuclastinib after meeting certain eligibility criteria.